Plasma exchange for severe immune-related adverse events from checkpoint inhibitors: an early window of opportunity?

Immune checkpoint inhibitors (ICIs) have revolutionized the treatment of several advanced malignancies leading to durable remission in a subset of patients. Their rapidly expanding use has led to an increased frequency of immune-related adverse events (irAEs). The pathogenesis of irAEs is poorly und...

Descripción completa

Detalles Bibliográficos
Autores principales: Katsumoto, Tamiko R, Wilson, Kalin L, Giri, Vinay K, Zhu, Han, Anand, Shuchi, Ramchandran, Kavitha J, Martin, Beth A, Yunce, Muharrem, Muppidi, Srikanth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257781/
https://www.ncbi.nlm.nih.gov/pubmed/35814850
http://dx.doi.org/10.1093/immadv/ltac012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9257781/
https://www.ncbi.nlm.nih.gov/pubmed/35814850
http://dx.doi.org/10.1093/immadv/ltac012

Ejemplares similares